Terminated EARLY_PHASE1 INTERVENTIONAL 1-arm NCT03371420

PET Imaging of Subjects Using 124I-PU-AD

PET Imaging of Subjects Using 124I-PU-AD: A Pilot Study

Sponsor: Memorial Sloan Kettering Cancer Center

Conditions Alzheimer Disease Lymphoma Myeloma Solid Malignancy

Interventions Blood Draws PET Scan PU-AD

Updated 9 times since 2017 Last updated: Apr 13, 2023 Started: Apr 30, 2016 Primary completion: Jun 10, 2019 Completion: Jun 10, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Company has ceased operations

Other terminated trials from Memorial Sloan Kettering Cancer Center

See all terminations from Memorial Sloan Kettering Cancer Center

Other Alzheimer Disease trials with similar outcome

Browse all Alzheimer Disease trials

Listed as NCT03371420, this EARLY_PHASE1 trial focuses on Alzheimer Disease and Lymphoma and remains terminated or withdrawn. Sponsored by Memorial Sloan Kettering Cancer Center, it has been updated 9 times since 2016, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Terminated EARLY_PHASE1
Jul 2024 — Sep 2024 [monthly]

Terminated EARLY_PHASE1
May 2023 — Jul 2024 [monthly]

Terminated EARLY_PHASE1

Status: Completed → Terminated
Jan 2021 — May 2023 [monthly]

Completed EARLY_PHASE1
Jul 2019 — Jan 2021 [monthly]

Completed EARLY_PHASE1

Status: Active Not Recruiting → Completed

▶ Show 4 earlier versions

Jun 2019 — Jul 2019 [monthly]

Active Not Recruiting EARLY_PHASE1
Apr 2019 — Jun 2019 [monthly]

Active Not Recruiting EARLY_PHASE1

Status: Recruiting → Active Not Recruiting
Jun 2018 — Apr 2019 [monthly]

Recruiting EARLY_PHASE1
Dec 2017 — Jun 2018 [monthly]

Recruiting EARLY_PHASE1

First recorded

Apr 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Memorial Sloan Kettering Cancer Center
Rockefeller University
Samus Therapeutics, Inc.
Weill Medical College of Cornell University

Data source: Samus Therapeutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New York, United States